A new review was published in Volume 16 of Oncotarget on June 17, 2025, titled "Optimizing enfortumab vedotin plus ...

Pembrolizumab demonstrated promising efficacy and safety in anaplastic thyroid cancer based on pooled survival and tumor ...

One of the biggest patent cliffs is set to hit the pharmaceutical industry this decade, with major players bracing for a blow ...

Pharmaceutical companies are heading toward a steep patent cliff that could strip more than $230 billion in US drug sales ...

Here, Michelle Tsai – chief operating officer at iOnctura – and Shane Olwill – chief development officer at Asgard ...

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

The approval comes amid speculation that AstraZeneca CEO Pascal Soriot is considering delisting its UK stock market listing for the US.

Neoadjuvant cobolimab and dostarlimab followed by surgery and adjuvant dostarlimab may confer benefits over perioperative pembrolizumab in patients with high-risk, resectable melanoma.

Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid ...

Pfizer has terminated a Phase II study of its CD47 immune checkpoint inhibitor, maplirpacept, due to low recruitment. In an ...

Discover the latest advancements in breast cancer treatment at the 24th Annual International Congress, featuring expert ...